Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 12

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 12
---
 adult vaccine portfolio of best - in - class products​ • Advance innovative pre - clinical and discovery efforts leveraging collaborations 1 2 3 4 Opportunistically Return Capital to Stockholders • C ontinue to evaluate landscape and opportunistically deliver capital to stockholders through share repurchase program to maximize value for stockholders 14 | We Have a Clear Path to Create Even Greater Value © Copyright DYNAVAX 2025

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 15 | © Copyright DYNAVAX 2025 Our Differentiated Expertise and Capabilities Will Enable Us to Succeed Superior Technology 1 Scalability 3 Fully Integrated Platform 2 Well - developed, proven capabilities in R&D, regulatory, manufacturing and commercialization Our pipeline can leverage the expertise and capabilities we developed to support HEPLISAV - B Proven, innovative adjuvant technology with a well - defined MOA and clinical profile — which is foundational to our ability to drive differentiated safety and efficacy among potential targets We Are Well Positioned for Success as a Commercial Stage Biotech Company A Diversified Commercial Portfolio + Robust Pipeline B Low - Cost Capital & Efficient Allocation Multiple commercial products provide a diversified revenue stream, which when supplemented by a robust pipeline, enable sustained, long - term growth Low - cost, certain capital enables a company to bring additional products to market in cost - effective way How to Succeed in Biotech

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 16 | Foundational Principles of Corporate Finance Underpin our Capital Allocation Framework © Copyright DYNAVAX 2025 Our thoughtful and deliberate approach to capital allocation has enabled successful execution of our long - term strategy “Corporate Finance 101” 1 Invest in assets and projects that yield the greatest rate of return 2 Choose a financing mix that maximizes the value of the investments made 3 If there are not enough investments that earn a satisfactory rate, return the cash to stockholders Our Capital Allocation Framework • Drive sustained growth in HEPLISAV - B • Progress our